Hormonal
Early combination therapy using low-hypoglycemia-risk agents (e.g., SGLT2 inhibitors or GLP-1 receptor agonists) combined with metformin at diagnosis is more effective than sequential stepwise therapy at maintaining glycemic targets and minimizing diabetes-related complications.
If you have just been diagnosed with Type 2 Diabetes, ask your doctor about starting with a combination of Metformin and another modern drug (like an SGLT2 inhibitor or GLP-1 agonist) right away, rather than waiting for your blood sugar to rise again. This approach keeps your blood sugar closer to normal levels for longer and protects your heart and kidneys better than starting with just one drug.
The VERIFY study demonstrated that early combination therapy is more effective at maintaining blood glucose levels within target ranges than is traditional stepwise therapy. Furthermore, patients could maintain glucose levels close to those of non-diabetic individuals for a longer duration.
Why this rating
Supported by large-scale, multicenter, randomized clinical trials (VERIFY, EMPA-REG, etc.).
Source
당뇨병 치료의 진화: 관해를 향해가는 혁신적 약물치료와 첨단 관리기기의 결합
Jong Han Choi et al. · Public Health Weekly Report · 2024
DOI 10.56786/phwr.2024.17.44.4
More from this paper
- SGLT2 inhibitors and GLP-1 receptor agonists provide significant cardiovascular and renal protective benefits independent of their blood glucose-lowering effects, making them suitable for treating heart failure and chronic kidney disease in diabetic patients.Strong
- Continuous Glucose Monitoring (CGM) and automated insulin delivery systems significantly improve glycemic control accuracy, reduce hypoglycemia risk, and enhance treatment adherence in patients with Type 1 Diabetes and insulin-treated Type 2 Diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →